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Treatment of pulmonary arterial hypertension in congenital  
heart disease in Singapore versus the Netherlands: age exceeds 
ethnicity in influencing clinical outcome
A.C.M.J. van Riel1,2 · M.J. Schuuring1 · I.D. van Hessen1 · A.P.J. van Dijk3 ·  
E.S. Hoendermis4 · J.W. Yip5 · B.J.M. Mulder1,2 · B.J. Bouma1
Results A total of 74 patients, 45 Dutch (mean age 47 ± 14 
years) and 29 Singaporean (mean age 41 ± 14 years) were 
analysed. Despite a lower 6MWT (312 versus 395 me-
tres, p = 0.01) and peak VO2 (35 versus 49 % of predicted, 
p = 0.01) at baseline in Singaporean patients, the treatment 
effect was similar in the two populations. Age at initiation 
of therapy (per 5 year lower age, β = + 4.5, p = 0.017) was 
the strongest predictor of improvement in exercise capac-
ity, corrected for ethnicity, baseline 6MWT, sex and CHD 
defect.
Conclusions Patients from Singapore had a worse clinical 
performance at baseline compared with the PAH-CHD pa-
tients from the Netherlands. No relation between ethnicity 
and improvement in 6MWT after PAH-specific therapy was 
found. Age at initiation of PAH-specific therapy was the 
strongest predictor of treatment efficacy and mortality, em-
phasising the need for early initiation of treatment in these 
patients.
Keywords Pulmonary arterial hypertension ·  
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Introduction
Patients with congenital heart disease (CHD) may suffer 
from pulmonary arterial hypertension (PAH), leading to 
increased morbidity and mortality [1]. With the emergence 
of disease-targeting therapies, including prostanoids, endo-
thelin receptor antagonists (ERAs) and phosphodiester-
ase-5 (PDE-5) inhibitors, it has become possible to improve 
symptoms and stabilise disease progression [2–4]. Current 
European Society of Cardiology guidelines recommend 
both ERAs and PDE-5 inhibitors as a class I-A indication 
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Abstract
Background Advanced treatment of pulmonary arterial 
hypertension (PAH) in congenital heart disease (CHD) is 
increasingly applied worldwide following the—mainly 
Western world based—international PAH-CHD guidelines. 
However, studies comparing clinical presentation and out-
come after the initiation of PAH-specific treatment are lack-
ing. We aimed to analyse this in a Singaporean and Dutch 
cohort of PAH-CHD patients.
Methods Adult CHD patients starting PAH-specific ther-
apy, enrolled in two nationwide registries, were analysed. 
Patients received phosphodiesterase-type-5 inhibitors, en-
dothelin receptor antagonists, or a combination. Change in 
six-minute walk test (6MWT) during follow-up was anal-
ysed using linear mixed model analysis. Determinants for 
mortality were assessed using Cox proportional hazard 
analyses.
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and outcomes has been described [11, 12], studies regarding 
ethnicity and geographical variations on treatment outcome 
are sparse. However, biological differences are known to 
exist in the production and handling of ET-1, a potent sys-
temic and pulmonary vasoconstrictor [13, 14]. Furthermore, 
socioeconomic factors and differences in healthcare systems 
could influence the effect of treatment in PAH-CHD [15]. 
We aimed to evaluate variations in clinical presentation and 
outcome after initiation of PAH-specific therapy in CHD 
patients from the Netherlands and Singapore.
Methods
Study population
In this multicentre study, all adult CHD patients receiv-
ing PAH-specific therapy and enrolled in two nationwide 
registries between 2004 and 2013, using uniform inclusion 
criteria, were included. Dutch patients were participants 
of a prospective multicentre study on the effects of bosen-
tan (ERA) therapy in PAH-CHD in the Netherlands [2, 4]. 
The patients from Singapore were enrolled in a dedicated 
PAH-CHD registry of the National University Hospital in 
Singapore at the start of PAH-specific therapy. PAH was 
diagnosed according to the guidelines in all patients [5].
In the Netherlands, all patients were started on treat-
ment with bosentan, as part of the prospective multicentre 
study mentioned previously. In Singapore, the type of PAH 
treatment was decided by the treating physician, taking into 
account medical insurance policies. In both countries, tim-
ing to the start of combination therapy was at the discretion 
of the treating physician, considering patient preferences 
and existing contraindications. Sildenafil was commonly 
started at 20 mg three times daily and tadalafil at 20 mg once 
daily, increasing to 40 mg once daily. Bosentan monother-
apy was started at 62.5 mg twice daily, increasing the dose 
to 125 mg twice daily after four weeks, as tolerated.
Data collection and outcome definition
Exercise capacity was evaluated using the six-minute walk 
test (6MWT) and cardiopulmonary exercise test (CPET). 
Transthoracic echocardiography was performed following 
the available guidelines in both centres [5]. Patients with 
Down syndrome were excluded from all analyses, due to 
previous reports indicating that the 6MWT is not a valid 
indicator of cardiorespiratory fitness in these patients [16].
Primary outcome was improvement in 6MWT during 
follow-up. To accommodate for expected differences in 
height and weight between the two populations, measure-
ments of the 6MWT were calculated as percentage of the 
predicted value, using the equation of Enright and Sherrill 
for therapy in PAH patients in New York Heart Associa-
tion (NYHA) functional class II or III [5]. Following these 
guidelines, PAH-specific treatment in CHD is increasingly 
applied worldwide [6]. However, these guidelines are based 
on randomised clinical trials which include only a small 
portion of CHD patients [7–9]. Furthermore, only 6–7 % of 
the patient cohort included in these trials is of Asian ethnic-
ity, although the general Asian population accounts for more 
than 60 % of the total world population [10]. While the influ-
ence of ethnicity on CHD prevalence, clinical presentation 
Table 1 Baseline clinical characteristics
All 
patients
The 
Netherlands
Singapore
(n = 74) (n = 45) (n = 29) p value
Age (years) 45 ± 14 47 ± 14 41 ± 14 0.11
Male sex, n (%) 23 (31) 14 (31) 9 (31) 0.99
Follow up (years) 3.7 ± 2.4 3.3 ± 2.2 4.4 ± 2.8 0.06
Height (cm) 163 ± 10 168 ± 8 158 ± 9 <0.01
Weight (kg) 61 ± 15 64 ± 14 57 ± 15 0.04
Body surface area 
(m2)
1.7 ± 0.2 1.7 ± 0.2 1.6 ± 0.2 <0.01
Eisenmenger syn-
drome, n (%)
57 (77) 32 (71) 25 (86) 0.13
Pretricuspid shunt, 
n (%)
33 (45) 16 (36) 17 (59) 0.05
Posttricuspid shunt, 
n (%)
41 (55) 29 (64) 12 (41)
Shunt closed, n (%) 4 (6) 2 (5) 2 (7) 0.67
Exercise capacity
NYHA functional 
class III, n (%)
55 (74) 32 (71) 23 (79) 0.36
peak VO2 (ml/min) 792 ± 344 970 ± 357 660 ± 275 <0.01
peak VO2 (% of 
predicted)
41 ± 16 49 ± 18 35 ± 11 0.01
Baseline 6MWT (m) 363 ± 136 395 ± 137 312 ± 121 0.01
Baseline 6MWT  
(% of predicted)
62 ± 24 68 ± 25 53 ± 21 0.02
Echocardiography
sPAP (mmHg) 84 ± 35 76 ± 32 99 ± 37 0.01
Impaired RV function, 
n (%)
17 (17) 8 (23) 9 (27) 0.67
Impaired LV function, 
n (%)
5 (5) 4 (11) 1 (3) 0.19
PAH medication, n 
(%)
ERA 45 (61) 45 (100) 0 <0.01
PDE-5 inhibitor 29 (39) 0 29 (100) <0.01
Combination therapy 
initiated
11 (15) 8 (18) 3 (10) 0.24
Discontinued PAH 
therapy
7 (10) 7 (16) 0 0.03
Values are presented as mean ± SD or as counts with percentages.
NYHA New York Heart Association, peak VO2 maximum oxygen 
consumption, 6MWT six-minute walk test, sPAP systolic pulmonary 
arterial pressure, RV right ventricular, LV left ventricular, PAH 
pulmonary arterial hypertension, ERA endothelin receptor 
antagonist, PDE-5 phosphodiesterase type 5.
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inhibitor (either sildenafil or tadalafil) as PAH treatment 
(Table 1). During follow-up, combination therapy consist-
ing of adding an ERA or a PDE-5 inhibitor, was started in 
18 % of the patients from the Netherlands and in 10 % of 
the Singapore patients (p = NS). In the course of the study 7 
Dutch patients (16 %) discontinued their PAH-specific ther-
apy. This was either due to amelioration of the pulmonary 
arterial pressures, patient preferences or the decision of the 
treating physician.
Exercise capacity
Exercise capacity was significantly different between the 
two groups (Table 1). The peak VO2 measured by CPET 
was higher in the Dutch population, both the absolute peak 
VO2 value (970 ± 357 vs. 660 ± 275 ml/min, p < 0.01) and 
the percentage of predicted peak VO2 (49 ± 18 vs. 42 ± 13 %, 
p = 0.01). The 6MWT showed similar differences between 
the two populations at baseline. Dutch patients were able 
to walk an average of 395 meters during 6MWT, versus a 
mean of 312 meters for the Singaporean patients (p = 0.01). 
This difference persisted after correction for sex, height and 
weight, which was used to calculate an expected 6MWT 
value for each individual patient (68 vs. 53 % of predicted 
6MWT, p = 0.02).
Clinical outcome
All CHD patients were regularly monitored by means 
of 6MWT measurements during the treatment of PAH. 
Figure 2a portrays the change in 6MWT distance during the 
first year of treatment in both cohorts. There was a clear and 
significant difference between the populations in 6MWT 
distance before the start of PAH-specific therapy, as noted 
previously, which persisted until the third month of treat-
ment (p < 0.02 for both). The Singaporean patients showed 
a significantly higher increase in 6MWT distance, com-
pared with the population from the Netherlands (p = 0.024). 
Figure 2b depicts the 6MWT distance expressed as a percent-
age of predicted. The differences between the two groups 
at baseline and three months remain, and even extend to 
the sixth month (p < 0.03 for all). Furthermore, besides the 
lower starting point for Singaporean patients, there was a 
significant difference in the change of 6MWT distance dur-
ing 12 months of treatment in both groups, when corrected 
for percentage of predicted values (p = 0.045). Of note, the 
6MWT measurements depicted in Fig. 2 are of survivors 
only, and the number of patients gradually decreases over 
time. Improvement in 6MWT was not significantly asso-
ciated with an improvement in NYHA functional class or 
right ventricular function measured by echocardiography.
Surprisingly, survival was significantly lower in the 
Dutch population, as depicted by Kaplan-Meier analysis in 
[17]. Improvement in 6MWT was defined as at least 10 % 
increase in 6MWT distance from baseline. Other parameters 
studied were peak VO2 at baseline and NYHA functional 
class and echocardiographic parameters at baseline and 
follow-up.
Statistical analysis
Data are summarised as number (%) or mean ± SD as appro-
priate. Categorical data were evaluated using the chi-square 
statistic. Independent sample t-test was used for compari-
son of continuous variables. A linear mixed model with an 
autoregressive residual covariance matrix and a random 
intercept for individual differences was used to analyse 
6MWT values during follow-up. Kaplan-Meier curves were 
plotted and log-rank test was performed to assess differences 
in the occurrence of mortality between the two cohorts. The 
relation between determinants and mortality was assessed 
using univariate and multivariate Cox proportional hazard 
analyses. Significant univariate determinants (entry thresh-
old p = 0.10) were entered in a multivariate model analysed 
with a backward conditional algorithm. All reported p val-
ues are two-sided, and values of p < 0.05 were considered 
significant. Data analysis was performed using SPSS 20.0 
(IBM).
Results
Patient cohort
A total of 74 PAH-CHD patients (29 Singaporean, 45 Dutch, 
mean age 45 ± 14 years, 31 % male) were analysed in this 
study (Fig. 1). Both populations were comparable regarding 
age, sex and mean duration of follow-up (Table 1), except 
for height (168 vs. 158 cm, p < 0.01) and weight (64 vs. 
57 kg, p = 0.04).
All Dutch patients were started on the ERA bosentan, 
while the entire Singaporean population received a PDE-5 
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Fig. 1 Derivation of the study population
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efit of PAH-specific treatment on exercise capacity in both 
populations starts to approach zero.
Discussion
This study elucidates the variations in clinical presentation 
and outcome of two CHD populations receiving PAH-spe-
cific therapy. While Singaporean patients had a significantly 
lower exercise capacity before treatment initiation, exercise 
capacity increased equally in both cohorts, despite a clear 
difference in choice of therapy. Furthermore, age at initia-
tion of PAH-specific therapy was shown to be the strongest 
determinant of treatment effect, when corrected for ethnic-
ity, sex, exercise capacity at baseline and CHD defect. This 
underlines the need for starting treatment early in these 
patients.
Global differences
There are several potential causes for the difference in 
exercise capacity before treatment initiation, which can 
be explained by several factors and not only by a differ-
ence in ethnicity itself. One explanation is the higher num-
ber - although not statistically significant—of Eisenmenger 
patients in the Singapore population. This could represent 
a more advanced disease state at the start of PAH-specific 
therapy, which is known to be associated with decreased 
exercise capacity [18, 19]. Furthermore, the anticipated 
difference in social economic status between the stud-
ied Dutch and Singaporean patients can explain the base-
line differences even more. As described by Wu et al. [15] 
PAH patients with a lower socioeconomic status have an 
increased risk of clinical worsening compared with patients 
with a higher socioeconomic status. One of the explanations 
for this difference is that PAH-targeted therapies impose 
Fig. 3 (log rank = 5.3, p = 0.02). However, when determin-
ing the relation between important clinical variables and 
mortality using multivariate Cox regression analysis, age at 
the start of advanced therapy was the most important pre-
dictor of mortality with a hazard ratio of 1.5 per 10 years 
of increasing age (95 % CI 1.1–2.1, p = 0.02) corrected for 
ethnicity, baseline 6MWT, sex and right ventricular function 
at baseline.
Determinants of change in six-minute walk distance
Using mixed model linear regression, age at start of therapy 
(per 5 years lower age) was found to be a significant deter-
minant of change in six-minute walk distance (Table 2), cor-
rected for baseline 6MWT, sex, ethnicity and CHD defect 
(β= + 4.5, p = 0.017). We performed a sensitivity analysis to 
assess the model performance when excluding outliers (top 
or bottom 5 %), which yielded the same predictor of treat-
ment efficacy: age at start of therapy (β = +2.3, p = 0.027). 
The effect of age at the start of therapy is further illustrated 
in Fig. 4, where it is clear that from the age of 45 the ben-
Fig. 2 Change in six-minute walk test (6MWT) a 6MWT during 
follow-up, absolute values, b 6MWT expressed as percentage of pre-
dicted distance, corrected for sex, height and weight ∆6MWT = change 
in 6MWT from baseline to 12-month follow-up between Singaporean 
and Dutch patients
 
Fig. 3 Kaplan-Meier curve estimates of overall survival according to 
country of origin
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the ability to improve exercise capacity during PAH treat-
ment. An explanation for the lack in improvement might be 
that PAH therapy antagonises the natural declining exercise 
capacity in older patients, leading to stabilisation of 6MWT 
rather than improvement. Furthermore, the disease of the 
pulmonary vasculature could be more advanced in patients 
presenting at older age, thereby limiting the ability in these 
patients to improve in functional capacity. An early initia-
tion of combination therapy might be beneficial in these 
older patients with regard to exercise capacity and possibly 
survival [29]. However, due to the retrospective nature of 
the study, we were unable to show if an earlier intervention 
would have prevented a decline in 6MWT in older patients.
Because CPET is a demanding test for patients and techni-
cians, the relatively simple 6MWT has frequently been used 
as a clinical endpoint and routine follow-up measurement 
for CHD-PAH patients. Indeed improvement of 6MWT is 
a valuable goal in these patients and reduces mortality and 
morbidity in the short term [2, 4]. However, meta-analysis 
has shown that changes in 6MWT do not predict long-term 
clinical events [30]. Therefore, future clinical studies should 
certainly focus on clinical worsening as a more meaningful 
endpoint.
a tremendous economic burden on Singaporean patients 
as they are not covered by insurance. While all residents 
from Singapore have compulsory basic medical insurance, 
only a small number have extended private medical insur-
ance (28 % in our cohort). These financial barriers may limit 
patient access to health services and appropriate treatment, 
imposing a disproportionate burden on those with a lower 
socioeconomic status. This is further facilitated by pulmo-
nary hypertension not being listed as one of the chronic con-
ditions that receive treatment reimbursement in Singapore 
[20]. This also explains the difference in choice for PAH-
specific treatment regimen, with the annual cost of sildenafil 
around $ 3300–$ 5500 versus ≈$ 36,700 for bosentan [15]. 
In the Netherlands, health insurance is also compulsory; 
however, both primary and hospital care is accessible for 
CHD patients without extra costs [21]. This is of clinical 
relevance, since quality of life in PAH-CHD patients has 
recently been associated with worse outcome [22, 23].
Effect of treatment on functional capacity
Previous results have reported the important effects of age 
on single exercise capacity measurements in CHD patients 
[24, 25]. In CHD patients with PAH a decreased exercise 
capacity is often present, due to the inability to increase car-
diac output sufficiently to meet increased demand [26]. Dur-
ing ageing, the loss of RV contractile reserve and increasing 
pulmonary dysfunction, combined with possible diastolic 
dysfunction of the left ventricle, further impairs the ability 
to increase cardiac output in these patients [27]. Addition-
ally, while the short-term prognosis of PAH-CHD patients 
is often good, a markedly increased morbidity and mortality 
has been shown with increasing patient age at the time of 
diagnosis [28]. In addition to a diminished exercise capac-
ity inherent to older age, we were now able to show that 
age has a significant negative influence on mortality and 
Table 2 Regression coefficients for determinants of percentage 
change of 6MWT from baseline
β 95 % CI p value
Female sex 4.0 − 14.1–22.2 0.66
Singaporean ethnicity 7.4 − 13.2–27.9 0.48
Age at start advanced therapy (per 
5 year lower)
4.5 0.8–8.1 0.017
Pretricuspid shunt 0.7 − 18.8–20.1 0.95
PDE-5 inhibitor treatment 7.4 − 13.2–27.9 0.48
6MWT six-minute walk test, PDE5 phosphodiesterase type 5.
KEY MESSAGE   Age at start of PAH-specific therapy was the main determinant of treatment efficacy, as described by 
                                  change in 6MWT. This emphasizes the need for early treatment initiation in these patients.
Fig. 4 Change in six minute walk 
test (6MWT) per age at point of in-
clusion (start PAH-specific therapy)
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Limitations
In this registry-based study we could not control exposure 
or outcome assessment, but instead needed to rely on oth-
ers for accurate record-keeping. This could have introduced 
selection bias in the patient cohort and measurements dur-
ing follow-up. Furthermore the population used in this study 
reflects the clinical and research workload of tertiary CHD 
centres, possibly introducing bias by favouring those with 
more symptoms and lower perceived functional capacity.
Conclusion
Patients from Singapore had a worse clinical performance 
at baseline compared with the PAH-CHD patients from the 
Netherlands. Age at initiation of PAH-specific therapy was 
the strongest predictor of treatment efficacy and mortality, 
emphasising the need for early initiation of treatment in 
these patients.
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